Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Göbel, U; Calaminus, G; Teske, C; Bamberg, M; Bökkerink, JP; Haas, RJ; Holschneider, AM; Janka-Schaub, G; Jürgens, H; Mittler, U.
BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89
KLIN PADIAT. 1993; 205(4): 231-240.
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Urban Ernst-Christian
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The treatment regimen of the ongoing cooperative study for non testicular germ cell tumors (MAKEI 89 of the German Society of Pediatric Oncology and Hematology), was stratified as in MAKEI 83 and 86 according to histology, localisation and stage. In the 1989 study, vinblastine was replaced by etoposide, resulting in a chemotherapeutic regimen of 3 to 4 courses BEP and 3 to 4 courses VIP in patients with stage I to IV. Total chemotherapy was reduced for 25%. In children under 1 year of age, bleomycin was omitted and bleomycin dose was reduced to 50%. In children up to 2 years because of two toxic deaths due to bleomycin who were registered in MAKEI 89 Pilot phase. Until Jan. 31, 1993, 230 patients were registered in the MAKEI 89 pilot study and the MAKEI 89 study, containing 186 protocol and 44 follow-up patients (patients with intracranial tumors are excluded for the review). 78 of the registered patients had a teratoma, 9 of these 78 patients suffered from a relapse. In 7 of 9 patients a lasting second remission has been achieved. 12 patients offered with germinoma. 1 of 12 patients had a recurrence but is in second remission. 47 patients had malignant non germinomatous germ cell tumors with an event free survival of 91 +/- 0.4%. 2 of the 47 patients relapsed and died. Toxicity was mainly hematologic without evidence of long term effects. Bleomycin induced pulmotoxicity (WHO grade IV) was documented in 1 protocol patient (see above). Nephrotoxicity with a grade III (WHO) decrease of creatinine clearance was found in 25% of the documented patients with a fast return to normal values after the end of therapy in most of the children. For the follow-up MAKEI 93 study, different topics are defined. 1. The value of chemotherapy for immature teratoma has to be discussed. 2. In invasive immature teratoma in children over 1 year of age, the effectiveness of chemotherapy should be proved. 3. Germinomas show high platinum sensitivity, therefore a platinum based chemotherapy has to be examined for this risk group. 4. The value of a wait and see strategy similar to the proved regimen in the French germ cell tumor protocol has to be verified in patients with stage I non germinomatous germ cell tumors. 5. An intensification of chemotherapy in patients with malignant stage III and IV non germinomatous germ cell tumors has to be examined as a new therapeutic approach for this risk group.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - administration and dosage
Child - administration and dosage
Child, Preschool - administration and dosage
Cisplatin - administration and dosage
Dose-Response Relationship, Drug - administration and dosage
Drug Administration Schedule - administration and dosage
Dysgerminoma - drug therapy
Etoposide - administration and dosage
Female - administration and dosage
Follow-Up Studies - administration and dosage
Humans - administration and dosage
Ifosfamide - administration and dosage
Infant - administration and dosage
Male - administration and dosage
Neoplasm Recurrence, Local - drug therapy
Neoplasm Staging - drug therapy
Neoplasms, Germ Cell and Embryonal - drug therapy
Ovarian Neoplasms - drug therapy
Pilot Projects - drug therapy
Prospective Studies - drug therapy
Teratoma - drug therapy
Vincristine - administration and dosage

© Med Uni Graz Impressum